Avastin's commercial march suffers setback

scientific article published on September 1, 2010

Avastin's commercial march suffers setback is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/NBT0910-879
P953full work available at URLhttp://www.nature.com/articles/nbt0910-879.pdf
http://www.nature.com/articles/nbt0910-879
P698PubMed publication ID20829807

P2093author name stringMalorye Allison
P2860cites workPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerQ29614302
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancerQ43111250
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsQ46464385
P433issue9
P407language of work or nameEnglishQ1860
P304page(s)879-880
P577publication date2010-09-01
P1433published inNature BiotechnologyQ1893837
P1476titleAvastin's commercial march suffers setback
P478volume28

Reverse relations

cites work (P2860)
Q37963955Benefit-risk assessment of bevacizumab in the treatment of breast cancer.
Q36248498Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Q83161956Can cancer clinical trials be fixed?
Q38003390Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions

Search more.